Back to News
Dec 24, 2025 12:10 PM

Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million

Gilead Sciences Inc. (NASDAQ:GILD) on Wednesday agreed to acquire Repare Therapeutics Inc.’s (NASDAQ:RPTX) polymerase theta (Polθ) ATPase inhibitor, RP-3467.

RP-3467 is being evaluated in the POLAR Phase 1 trial to evaluate its safety, pharmacokinetics, pharmacodynamics, and preliminary activity alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma.

“We are pleased to announce this transaction, which combines Gilead’s leading expertise in oncology research and development with RP-3467, a potential best-in-class Polθ ATPase inhibitor,” ...